Global strategies to fight carbapenem-resistant Acinetobacter baumannii (CRAB) infections - PubMed
4 hours ago
- #Global health
- #CRAB
- #Antimicrobial resistance
- Carbapenem-resistant Acinetobacter baumannii (CRAB) is a major healthcare-associated pathogen, especially in ICUs, causing severe infections with high mortality.
- CRAB's global epidemiology, carbapenem resistance mechanisms, and clinical significance of hetero-resistance are reviewed.
- Advanced diagnostic technologies like whole-genome sequencing, digital PCR, and CRISPR-based platforms help detect resistance and hetero-resistant subpopulations.
- Current treatments include optimized antibiotic combinations and emerging agents like sulbactam-durlobactam and cefiderocol.
- Alternative therapies such as bacteriophage therapy, antimicrobial peptidomimetics, and immune-modulating adjuncts are being explored.
- Infection prevention, antimicrobial stewardship, and global surveillance are crucial in limiting CRAB transmission.
- A multidisciplinary strategy integrating diagnostics, therapeutics, and public health policies is essential to control CRAB infections.